אסטוניה - אסטונית - Ravimiamet

agfa healthcare imaging agents gmbh - gadoteerhape - süstelahus - 279,32mg 1ml 5ml 1tk; 279,32mg 1ml 10ml 10tk; 279,32mg 1ml 60ml 10tk; 279,32mg 1ml 15ml 1tk; 279,32mg 1ml 20ml 10tk; 279,32mg 1ml 60ml 1tk

אסטוניה - אסטונית - Ravimiamet

orivas uab - fluotsinoloonatsetoniid+tsiprofloksatsiin - kõrvatilgad, lahus üheannuselises konteineris - 0,25mg+3mg 1ml 0.25ml 15tk

האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

instituto grifols s.a. - inimese normaalne immunoglobuliin - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - suguhormoonid ja immunoglobuliinid, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

csl behring gmbh - inimeste koagulatsiooni faktor viii, inimese von willebrand faktori - hemophilia a; von willebrand diseases - blood coagulation factors, von willebrand factor and coagulation factor viii in combination, antihemorrhagics - von willebrand haigus (vwd)profülaktika ja ravi hemorraagia või kirurgilise verejooksu patsientidel vwd, kui desmopressin (ddavp) ravi üksi on ebaefektiivne või vastunäidustatud. hemofiilia (kaasasündinud tegur-viii puudulikkus)profülaktikaks ja raviks verejooksu patsientidel, kellel on hemofiilia a.

אסטוניה - אסטונית - Ravimiamet

octapharma (ip) - immunoglobuliin, intravaskulaarseks kasutamiseks - infusioonilahus - 100mg 1ml 50ml 1tk; 100mg 1ml 25ml 1tk; 100mg 1ml 60ml 1tk; 100mg 1ml 200ml 3tk; 100mg 1ml 10ml 1tk; 100mg 1ml 100ml 1tk

אסטוניה - אסטונית - Ravimiamet

sandoz pharmaceuticals d.d. - valproehape - toimeainet prolongeeritult vabastav tablett - 500mg 30tk; 500mg 100tk; 500mg 20tk; 500mg 200tk; 500mg 90tk; 500mg 60tk; 500mg 50tk

אסטוניה - אסטונית - Ravimiamet

octapharma (ip) - immunoglobuliin, ekstravaskulaarseks kasutamiseks - süstelahus - 165mg 1ml 10ml 1tk; 165mg 1ml 24ml 1tk; 165mg 1ml 6ml 10tk; 165mg 1ml 24ml 10tk; 165mg 1ml 48ml 20tk; 165mg 1ml 48ml 1tk; 165mg 1ml 20ml 10tk; 165mg 1ml 12ml 1tk; 165mg 1ml 10ml 10tk; 165mg 1ml 10ml 20tk; 165mg 1ml 6ml 1tk; 165mg 1ml 20ml 20tk; 165mg 1ml 20ml 1tk; 165mg 1ml 12ml 20tk; 165mg 1ml 6ml 20tk; 165mg 1ml 24ml 20tk

אסטוניה - אסטונית - Ravimiamet

octapharma (ip) - immunoglobuliin, ekstravaskulaarseks kasutamiseks - süstelahus - 165mg 1ml 10ml 1tk; 165mg 1ml 20ml 20tk; 165mg 1ml 12ml 10tk; 165mg 1ml 48ml 20tk; 165mg 1ml 24ml 1tk; 165mg 1ml 20ml 1tk; 165mg 1ml 6ml 10tk; 165mg 1ml 48ml 10tk; 165mg 1ml 12ml 20tk; 165mg 1ml 10ml 10tk; 165mg 1ml 24ml 20tk; 165mg 1ml 10ml 20tk; 165mg 1ml 6ml 20tk; 165mg 1ml 12ml 1tk; 165mg 1ml 20ml 10tk; 165mg 1ml 6ml 1tk

אסטוניה - אסטונית - Ravimiamet

sandoz pharmaceuticals d.d. - valproehape - toimeainet prolongeeritult vabastav tablett - 300mg 30tk; 300mg 200tk; 300mg 50tk; 300mg 100tk

האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastilised ained - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies.  follicular lymphoma (fl) that is refractory to at least two prior  systemic therapies.